T
Takahiro Kamio
Researcher at Daiichi Sankyo
Publications - 11
Citations - 539
Takahiro Kamio is an academic researcher from Daiichi Sankyo. The author has contributed to research in topics: Trastuzumab & Medicine. The author has an hindex of 3, co-authored 6 publications receiving 174 citations.
Papers
More filters
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara,Yung-Jue Bang,Satoru Iwasa,Naotoshi Sugimoto,Min-Hee Ryu,Daisuke Sakai,Hyun-Cheol Chung,Hisato Kawakami,Hiroshi Yabusaki,Jeeyun Lee,Kaku Saito,Yoshinori Kawaguchi,Takahiro Kamio,Akihito Kojima,Masahiro Sugihara,Kensei Yamaguchi,DESTINY-Gastric Investigators +16 more
TL;DR: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based lin...
Journal ArticleDOI
1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
Kensei Yamaguchi,Y.-J. Bang,Satoru Iwasa,Naotoshi Sugimoto,M-H. Ryu,D. Sakai,H.C. Chung,Hisato Kawakami,Hiroshi Yabusaki,J.W. Lee,Kaku Saito,Yoshinori Kawaguchi,Takahiro Kamio,Akihito Kojima,Masahiro Sugihara,K. Shitara +15 more
Proceedings ArticleDOI
Abstract P1-18-12: A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer
Toshinari Yamashita,Akihiko Shimomura,Toshimi Takano,Yasuaki Sagara,Junichiro Watanabe,Eriko Tokunaga,Kunika Kikumori,Emi Kamiyama,Takahiro Kamio,Ryo Nakamura,Tetsu Shinkai,Shunji Takahashi +11 more
TL;DR: A phase 1 study assessing the QTc interval (by 12-lead ECG) and pharmacokinetics (PK) in subjects with HER2-expressing metastatic BC and the PK profile of total anti-HER2 antibody was similar to that of T-DXd; MAAA-1181a exposure was low.
Journal ArticleDOI
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
Kensei Yamaguchi,Yung-Jue Bang,Satoru Iwasa,Naotoshi Sugimoto,Min-Hee Ryu,Daisuke Sakai,Hyun Cheol Chung,Hisato Kawakami,Hiroshi Yabusaki,Jeeyun Lee,Kaku Saito,Yoshinori Kawaguchi,Takahiro Kamio,Akihito Kojima,Masahiro Sugihara,Kohei Shitara +15 more
TL;DR: T-DXd is an antibody–drug conjugate comprising an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a topoisomerase I inhibitor that binds to H2O through a “spatially aggregating” mechanism.
Journal ArticleDOI
Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
Kensei Yamaguchi,Y. Ban,Satoru Iwata,Naoki Sugimoto,Min-Hee Ryu,Daisuke Sakai,Hyun Cheol Chung,Hisato Kawakami,Hiroshi Yabusaki,Jeeyun Lee,Tatsu Shimoyama,Keun Wook Lee,Kaku Saito,Yoshinori Kawaguchi,Takahiro Kamio,Akihito Kojima,Masahiro Sugihara,Kohei Shitara +17 more
TL;DR: In this paper , trastuzumab deruxtecan (T-DXd) was used in human epidermal growth factor receptor 2 (HER2)-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.